Shopping Cart 0
Cart Subtotal
AED 0

Molecular Partners AG (MOLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that provides biological drugs. The company provides advanced pipeline products such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with pharmaceutical company to strengthen drug platforms through in-house development, licensing, collaboration, and others. Molecular Partners is headquartered in Zurich, Switzerland.

Molecular Partners AG (MOLN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Molecular Partners AG, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Molecular Partners and AstraZeneca Enter into Partnership 11

Molecular Partners Reinforces Partnership with Allergan 12

Allergan Exercises Option Agreement with Molecular Partners 13

Equity Offering 14

Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14

Molecular Partners Announces Partial Exercise of Underwriter's Option for IPO for USD108 Million 15

Molecular Partners AG-Key Competitors 17

Molecular Partners AG-Key Employees 18

Molecular Partners AG-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Financial Announcements 20

Aug 30, 2018: Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018 20

Feb 08, 2018: Molecular Partners Reports Significant Progress of Pipeline and Preliminary Unaudited Key Financials for 2017-Key Value Inflection Points in 2018 23

Aug 30, 2017: Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead 26

Feb 09, 2017: Molecular Partners reports preliminary unaudited key financials for 2016: Advancements across all therapeutic areas-Ongoing strong cash position 29

Corporate Communications 31

Jun 21, 2018: Molecular Partners Names Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company 31

May 12, 2017: Patrick Amstutz Appointed as Chief Executive Officer 32

May 11, 2017: Shareholders of Molecular Partners approved all Board proposals at the Annual General Meeting-Gwen Fyfe elected new Board member 33

Apr 12, 2017: Christian Zahnd appointed as Honorary Chairman of the Board of Directors as he decided not to stand for re-election as member of the Board of Directors at the Annual General Meeting 2017 34

Product News 35

11/09/2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology 35

Other Significant Developments 36

Apr 26, 2018: Further MP0250 clinical data and partner interest underline Molecular Partners' continued progress of its proprietary oncology compounds 36

Oct 26, 2017: Molecular Partners: Interim Management Statement Q3 2017 39

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Molecular Partners AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Molecular Partners AG, Deals By Therapy Area, 2012 to YTD 2018 8

Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Molecular Partners and AstraZeneca Enter into Partnership 11

Molecular Partners Reinforces Partnership with Allergan 12

Allergan Exercises Option Agreement with Molecular Partners 13

Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14

Molecular Partners Announces Partial Exercise of Underwriter's Option for IPO for USD108 Million 15

Molecular Partners AG, Key Competitors 17

Molecular Partners AG, Key Employees 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Molecular Partners AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that provides biological drugs. The company provides advanced pipeline products such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with pharmaceutical company to strengthen drug platforms through in-house development, licensing, collaboration, and others. Molecular Partners is headquartered in Zurich, Switzerland.

Molecular Partners AG (MOLN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Molecular Partners AG, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Molecular Partners and AstraZeneca Enter into Partnership 11

Molecular Partners Reinforces Partnership with Allergan 12

Allergan Exercises Option Agreement with Molecular Partners 13

Equity Offering 14

Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14

Molecular Partners Announces Partial Exercise of Underwriter's Option for IPO for USD108 Million 15

Molecular Partners AG-Key Competitors 17

Molecular Partners AG-Key Employees 18

Molecular Partners AG-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Financial Announcements 20

Aug 30, 2018: Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018 20

Feb 08, 2018: Molecular Partners Reports Significant Progress of Pipeline and Preliminary Unaudited Key Financials for 2017-Key Value Inflection Points in 2018 23

Aug 30, 2017: Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead 26

Feb 09, 2017: Molecular Partners reports preliminary unaudited key financials for 2016: Advancements across all therapeutic areas-Ongoing strong cash position 29

Corporate Communications 31

Jun 21, 2018: Molecular Partners Names Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company 31

May 12, 2017: Patrick Amstutz Appointed as Chief Executive Officer 32

May 11, 2017: Shareholders of Molecular Partners approved all Board proposals at the Annual General Meeting-Gwen Fyfe elected new Board member 33

Apr 12, 2017: Christian Zahnd appointed as Honorary Chairman of the Board of Directors as he decided not to stand for re-election as member of the Board of Directors at the Annual General Meeting 2017 34

Product News 35

11/09/2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology 35

Other Significant Developments 36

Apr 26, 2018: Further MP0250 clinical data and partner interest underline Molecular Partners' continued progress of its proprietary oncology compounds 36

Oct 26, 2017: Molecular Partners: Interim Management Statement Q3 2017 39

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Molecular Partners AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Molecular Partners AG, Deals By Therapy Area, 2012 to YTD 2018 8

Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9

Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Molecular Partners and AstraZeneca Enter into Partnership 11

Molecular Partners Reinforces Partnership with Allergan 12

Allergan Exercises Option Agreement with Molecular Partners 13

Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14

Molecular Partners Announces Partial Exercise of Underwriter's Option for IPO for USD108 Million 15

Molecular Partners AG, Key Competitors 17

Molecular Partners AG, Key Employees 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Molecular Partners AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.